AU2007254190A1 - Integrase inhibitors - Google Patents

Integrase inhibitors Download PDF

Info

Publication number
AU2007254190A1
AU2007254190A1 AU2007254190A AU2007254190A AU2007254190A1 AU 2007254190 A1 AU2007254190 A1 AU 2007254190A1 AU 2007254190 A AU2007254190 A AU 2007254190A AU 2007254190 A AU2007254190 A AU 2007254190A AU 2007254190 A1 AU2007254190 A1 AU 2007254190A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
pct
optionally substituted
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007254190A
Other languages
English (en)
Inventor
Zhenhong R. Cai
Salman Y. Jabri
Haolun Jin
Rachael A. Lansdown
Samuel E. Metobo
Michael L. Mish
Richard Pastor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2007254190A1 publication Critical patent/AU2007254190A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007254190A 2006-05-16 2007-05-16 Integrase inhibitors Abandoned AU2007254190A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80102006P 2006-05-16 2006-05-16
US60/801,020 2006-05-16
PCT/US2007/011851 WO2007136714A2 (en) 2006-05-16 2007-05-16 Integrase inhibitors

Publications (1)

Publication Number Publication Date
AU2007254190A1 true AU2007254190A1 (en) 2007-11-29

Family

ID=38573219

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007254190A Abandoned AU2007254190A1 (en) 2006-05-16 2007-05-16 Integrase inhibitors

Country Status (7)

Country Link
US (2) US20090306054A1 (enExample)
EP (1) EP2066670A2 (enExample)
JP (1) JP2009537546A (enExample)
AU (1) AU2007254190A1 (enExample)
CA (1) CA2651579A1 (enExample)
NZ (1) NZ572367A (enExample)
WO (1) WO2007136714A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090291921A1 (en) * 2007-11-20 2009-11-26 Gilead Sciences, Inc. Integrase inhibitors
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US9018227B2 (en) 2010-03-19 2015-04-28 Indiana State University Nicotinic acetylcholine receptor agonists
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
KR102000382B1 (ko) 2015-02-03 2019-07-15 화이자 인코포레이티드 신규 시클로프로파벤조푸라닐 피리도피라진디온
CN106632397B (zh) * 2016-12-01 2019-03-22 齐鲁天和惠世制药有限公司 一种6α-溴青霉烷-3α-羧酸二苯甲酯-1β-氧化物的制备方法
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
CN112142714A (zh) * 2019-06-27 2020-12-29 山东润博生物科技有限公司 一种灭草烟的合成方法
CN112142712A (zh) * 2019-06-27 2020-12-29 山东润博生物科技有限公司 一种甲基咪草烟的合成方法
CN112142713A (zh) * 2019-06-27 2020-12-29 山东润博生物科技有限公司 一种咪草烟的合成方法
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2083580T3 (es) 1990-06-13 1996-04-16 Arnold Glazier Profarmacos de fosforo.
DK0481214T3 (da) * 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU4225499A (en) 1998-06-03 1999-12-20 Merck & Co., Inc. Hiv integrase inhibitors
WO1999062513A1 (en) 1998-06-03 1999-12-09 Merck & Co., Inc. Hiv integrase inhibitors
WO2000036132A1 (en) 1998-12-14 2000-06-22 Merck & Co., Inc. Hiv integrase inhibitors
BR9916583A (pt) 1998-12-25 2001-09-25 Shionogi & Co Derivados heteroaromáticos tendo uma atividade inibitória contra integrase de hiv
EP1186599A4 (en) * 1999-06-02 2003-02-26 Shionogi & Co NOVEL PROCESS FOR THE PREPARATION OF SUBSTITUTED PROPENONE DERIVATIVES
WO2001000578A1 (en) 1999-06-25 2001-01-04 Merck & Co., Inc. 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
US6245806B1 (en) 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
AU8009900A (en) 1999-10-13 2001-04-23 Merck & Co., Inc. Hiv integrase inhibitors
AU2002230392A1 (en) 2000-10-12 2002-05-15 Merck & Co., Inc. AZA-and polyaza-naphthalenyl ketones useful as HIV integrase inhibitors
EP1326865B1 (en) 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
AU1532802A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
ATE404537T1 (de) * 2002-08-13 2008-08-15 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
CN1812992A (zh) 2003-04-28 2006-08-02 泰博特克药品有限公司 Hiv整合酶抑制剂
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
US7919623B2 (en) 2004-02-04 2011-04-05 Shionogi & Co., Ltd. Naphthyridine derivatives having inhibitory activity against HIV integrase
SI1742642T1 (sl) 2004-04-14 2009-04-30 Gilead Sciences Inc Fosfonatni analogi inhibitorskih spojin HIV integraze
US20070072831A1 (en) 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
EP1973908A2 (en) 2005-12-21 2008-10-01 Gilead Sciences, Inc. Processes and intermediates useful for preparing integrase inhibitor compounds

Also Published As

Publication number Publication date
CA2651579A1 (en) 2007-11-29
JP2009537546A (ja) 2009-10-29
WO2007136714A2 (en) 2007-11-29
WO2007136714A3 (en) 2008-12-18
US8008287B2 (en) 2011-08-30
US20080058315A1 (en) 2008-03-06
US20090306054A1 (en) 2009-12-10
NZ572367A (en) 2011-09-30
EP2066670A2 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
US8008287B2 (en) Integrase inhibitors
US20070072831A1 (en) Integrase inhibitor compounds
AU2020353005B2 (en) Phosphodiesterase inhibitors and use
EP1664046B1 (en) Aza-quinolinol phosphonate integrase inhibitor compounds
JP6289485B2 (ja) Ｐｄｅ４のヘテロアリール阻害剤
WO2009067541A2 (en) Integrase inhibitors
IL270025B1 (en) Indole ahr inhibitors and uses thereof
ES2859510T3 (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar las infecciones por ortomixovirus
US20040167124A1 (en) Pre-organized tricyclic integrase inhibitor compounds
JP2006514099A5 (enExample)
CA3199496A1 (en) Heterocycle derivatives for treating trpm3 mediated disorders
AU2003231766A1 (en) Non nucleoside reverse transcriptase inhibitors
BG107285A (bg) Бета - карболинови производни като инхибитори на фосфодиестераза
HUP0302226A2 (hu) Foszfodiészteráz inhibitorokként alkalmazható szubsztituált pirrolopiridinon-származékok, ezek intermedierjei és a vegyületeket tartalmazó gyógyszerkészítmények
AU2005249363A1 (en) Phosphonate analogs of HIV integrase inhibitor compounds
AU2005206511A1 (en) Pyrimidyl phosphonate antiviral compounds and methods of use
CA3257043A1 (en) INDOLIZINE DERIVATIVES FOR THE TREATMENT OF TRPM3-MEDICATED DISORDERS
TW202411233A (zh) 用於治療trpm3介導病症之新型衍生物
JP2011529085A (ja) 抗ウイルス化合物
CN101128204A (zh) 2,4-二氨基-吡啶并嘧啶衍生物及其作为mTOR抑制剂的用途
KR20250034303A (ko) Trpm3-매개 장애를 치료하기 위한 인다졸 유도체
KR20250029065A (ko) TRPM3-매개 장애를 치료하기 위한 피라졸로[1,5-a]피리딘 유도체
CA2330110A1 (en) 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application